Nivolumab Plus Relatlimab Demonstrates Consistent Benefit for Patients with Advanced Melanoma
Source: OncLive, May 2023
Two-year follow-up data from the RELATIVITY-047 trial (NCT03470922) showed a continued benefit for patients with previously untreated, unresectable, or metastatic melanoma receiving nivolumab plus relatlimab (Opdualag) vs nivolumab (Opdivo) monotherapy supporting the use of the combination, according to Hussein A. Tawbi, MD, PhD.
The updated progression-free survival (PFS) analysis data presented by Tawbi during the 2023 ASCO Annual Meeting favored the combination as patients receiving nivolumab plus relatlimab (n = 355) achieved a median PFS of 10.2 months (95% CI, 6.5-14.8) vs 4.6 months (95% CI, 3.5-6.5) for those given nivolumab monotherapy (n = 359; HR, 0.81; 95% CI, 0.67-0.97). Median overall survival (OS) was not reached in the doublet arm (95% CI, 31.5-NA) and was 33.2 months (95% CI, 25.2-45.8) in the monotherapy arm (HR, 0.82; 95% CI, 0.67-1.02).
“The phase 3 trial RELATIVITY-047 had shown an improvement in PFS that was statistically significant and hit the primary end point even at a median follow-up of only 13.2 months. This has resulted in the FDA approval of this combination in the first line for patients with metastatic melanoma,” said Tawbi, who is the director of personalized cancer therapy and deputy chair in the Department of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center.